VALIDATED EXECUTIVE ENGAGEMENTS
OUTREACH
3914
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
703
Interactions with Platform & by Email
PARTICIPANTS
117
Unique # Participated
VALIDATIONS
53
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JUL 2020
TABLES
210
PAGES
285
EDITION
19
PRICE
USD $5450
Tapping into New Geographical Markets is a Great Way to Grow!
What's Your Addressable Opportunity in the Multiple Sclerosis Therapeutics Market?
Amid the COVID-19 crisis, the global market for Multiple Sclerosis Therapeutics estimated at US$20.3 Billion in the year 2020, is projected to reach a revised size of US$22.3 Billion by 2027, growing at a CAGR of 1.3% over the analysis period 2020-2027. Beta Interferon, one of the segments analyzed in the report, is projected to record a 1.4% CAGR and reach US$3.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Corticosteroids segment is readjusted to a revised 1.7% CAGR for the next 7-year period.
The Multiple Sclerosis Therapeutics market in the U.S. is estimated at US$5.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2027 trailing a CAGR of 2.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0% and 1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.4% CAGR.
In the global Monoclonal Antibodies segment, USA, Canada, Japan, China and Europe will drive the 1.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$3.8 Billion in the year 2020 will reach a projected size of US$4.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.9 Billion by the year 2027, while Latin America will expand at a 1.9% CAGR through the analysis period. We bring years of research experience to this 19th edition of our report. The 285-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
AbbVie, Inc.; Bayer AG; Biogen, Inc.; Merck & Co., Inc.; Novartis International AG; Pfizer, Inc.; Sanofi; Teva Pharmaceutical Industries Ltd.
» Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents and Other Drug Classes) » Therapeutics (Oral and Injection)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Global Competitor Market Shares |
| Multiple Sclerosis Therapeutics Competitor Market Share Scenario Worldwide (in %): 2019 & 2028 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| Multiple Sclerosis Therapeutics Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 |
| Multiple Sclerosis Therapeutics Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 |
| Multiple Sclerosis Therapeutics Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 |
| Beta Interferon (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025 |
| Beta Interferon (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 |
| Beta Interferon (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 |
| Corticosteroids (Drug Class) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 |
| Corticosteroids (Drug Class) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 |
| Corticosteroids (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 |
| Monoclonal Antibodies (Drug Class) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 |
| Monoclonal Antibodies (Drug Class) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 |
| Monoclonal Antibodies (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Antineoplastic Agents (Drug Class) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025 |
| Antineoplastic Agents (Drug Class) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 |
| Antineoplastic Agents (Drug Class) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 |
| Other Drug Class (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025 |
| Other Drug Class (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 |
| Other Drug Class (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Oral (Therapeutics) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025 |
| Oral (Therapeutics) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017 |
| Oral (Therapeutics) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 |
| Injection (Therapeutics) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025 |
| Injection (Therapeutics) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017 |
| Injection (Therapeutics) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| United States |
| Market Facts & Figures |
| US Multiple Sclerosis Therapeutics Market Share (in %) by Company: 2019 & 2025 |
| United States Multiple Sclerosis Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025 |
| Multiple Sclerosis Therapeutics Market in the United States by Drug Class: A Historic Review in US$ Million for 2009-2017 |
| United States Multiple Sclerosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| United States Multiple Sclerosis Therapeutics Market Estimates and Projections in US$ Million by Therapeutics: 2018 to 2025 |
| Multiple Sclerosis Therapeutics Market in the United States by Therapeutics: A Historic Review in US$ Million for 2009-2017 |
| United States Multiple Sclerosis Therapeutics Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025 |
| Canada |
| Canadian Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025 |
| Canadian Multiple Sclerosis Therapeutics Historic Market Review by Drug Class in US$ Million: 2009-2017 |
| Multiple Sclerosis Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| Canadian Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Therapeutics: 2018 to 2025 |
| Canadian Multiple Sclerosis Therapeutics Historic Market Review by Therapeutics in US$ Million: 2009-2017 |
| Multiple Sclerosis Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Therapeutics for 2009, 2019, and 2025 |
| Japan |
| Japanese Market for Multiple Sclerosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Japan: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017 |
| Japanese Multiple Sclerosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Japanese Market for Multiple Sclerosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Therapeutics for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Japan: Historic Sales Analysis in US$ Million by Therapeutics for the Period 2009-2017 |
| Japanese Multiple Sclerosis Therapeutics Market Share Analysis by Therapeutics: 2009 VS 2019 VS 2025 |
| China |
| Chinese Multiple Sclerosis Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Historic Market Analysis in China in US$ Million by Drug Class: 2009-2017 |
| Chinese Multiple Sclerosis Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Chinese Multiple Sclerosis Therapeutics Market Growth Prospects in US$ Million by Therapeutics for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Historic Market Analysis in China in US$ Million by Therapeutics: 2009-2017 |
| Chinese Multiple Sclerosis Therapeutics Market by Therapeutics: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Europe |
| Market Facts & Figures |
| European Multiple Sclerosis Therapeutics Market: Competitor Market Share Scenario (in %) for 2019 & 2025 |
| European Multiple Sclerosis Therapeutics Market Demand Scenario in US$ Million by Region/Country: 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 |
| European Multiple Sclerosis Therapeutics Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 |
| European Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017 |
| European Multiple Sclerosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| European Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Therapeutics: 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Europe in US$ Million by Therapeutics: A Historic Review for the Period 2009-2017 |
| European Multiple Sclerosis Therapeutics Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025 |
| France |
| Multiple Sclerosis Therapeutics Market in France by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025 |
| French Multiple Sclerosis Therapeutics Historic Market Scenario in US$ Million by Drug Class: 2009-2017 |
| French Multiple Sclerosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Multiple Sclerosis Therapeutics Market in France by Therapeutics: Estimates and Projections in US$ Million for the Period 2018-2025 |
| French Multiple Sclerosis Therapeutics Historic Market Scenario in US$ Million by Therapeutics: 2009-2017 |
| French Multiple Sclerosis Therapeutics Market Share Analysis by Therapeutics: 2009 VS 2019 VS 2025 |
| Germany |
| Multiple Sclerosis Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025 |
| German Multiple Sclerosis Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017 |
| German Multiple Sclerosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Multiple Sclerosis Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Therapeutics for the Period 2018-2025 |
| German Multiple Sclerosis Therapeutics Historic Market Analysis in US$ Million by Therapeutics: 2009-2017 |
| German Multiple Sclerosis Therapeutics Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025 |
| Italy |
| Italian Multiple Sclerosis Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Historic Market Analysis in Italy in US$ Million by Drug Class: 2009-2017 |
| Italian Multiple Sclerosis Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Italian Multiple Sclerosis Therapeutics Market Growth Prospects in US$ Million by Therapeutics for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Historic Market Analysis in Italy in US$ Million by Therapeutics: 2009-2017 |
| Italian Multiple Sclerosis Therapeutics Market by Therapeutics: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| United Kingdom |
| United Kingdom Market for Multiple Sclerosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017 |
| United Kingdom Multiple Sclerosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| United Kingdom Market for Multiple Sclerosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Therapeutics for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Million by Therapeutics for the Period 2009-2017 |
| United Kingdom Multiple Sclerosis Therapeutics Market Share Analysis by Therapeutics: 2009 VS 2019 VS 2025 |
| Spain |
| Spanish Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025 |
| Spanish Multiple Sclerosis Therapeutics Historic Market Review by Drug Class in US$ Million: 2009-2017 |
| Multiple Sclerosis Therapeutics Market in Spain: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| Spanish Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Therapeutics: 2018 to 2025 |
| Spanish Multiple Sclerosis Therapeutics Historic Market Review by Therapeutics in US$ Million: 2009-2017 |
| Multiple Sclerosis Therapeutics Market in Spain: Percentage Share Breakdown of Sales by Therapeutics for 2009, 2019, and 2025 |
| Russia |
| Russian Multiple Sclerosis Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025 |
| Multiple Sclerosis Therapeutics Market in Russia by Drug Class: A Historic Review in US$ Million for 2009-2017 |
| Russian Multiple Sclerosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Russian Multiple Sclerosis Therapeutics Market Estimates and Projections in US$ Million by Therapeutics: 2018 to 2025 |
| Multiple Sclerosis Therapeutics Market in Russia by Therapeutics: A Historic Review in US$ Million for 2009-2017 |
| Russian Multiple Sclerosis Therapeutics Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025 |
| Rest of Europe |
| Rest of Europe Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Rest of Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017 |
| Rest of Europe Multiple Sclerosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Rest of Europe Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Therapeutics: 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Rest of Europe in US$ Million by Therapeutics: A Historic Review for the Period 2009-2017 |
| Rest of Europe Multiple Sclerosis Therapeutics Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025 |
| Asia-Pacific |
| Asia-Pacific Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017 |
| Asia-Pacific Multiple Sclerosis Therapeutics Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 |
| Multiple Sclerosis Therapeutics Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Asia-Pacific Multiple Sclerosis Therapeutics Historic Market Scenario in US$ Million by Drug Class: 2009-2017 |
| Asia-Pacific Multiple Sclerosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Multiple Sclerosis Therapeutics Market in Asia-Pacific by Therapeutics: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Asia-Pacific Multiple Sclerosis Therapeutics Historic Market Scenario in US$ Million by Therapeutics: 2009-2017 |
| Asia-Pacific Multiple Sclerosis Therapeutics Market Share Analysis by Therapeutics: 2009 VS 2019 VS 2025 |
| Australia |
| Multiple Sclerosis Therapeutics Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025 |
| Australian Multiple Sclerosis Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017 |
| Australian Multiple Sclerosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Multiple Sclerosis Therapeutics Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Therapeutics for the Period 2018-2025 |
| Australian Multiple Sclerosis Therapeutics Historic Market Analysis in US$ Million by Therapeutics: 2009-2017 |
| Australian Multiple Sclerosis Therapeutics Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025 |
| India |
| Indian Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025 |
| Indian Multiple Sclerosis Therapeutics Historic Market Review by Drug Class in US$ Million: 2009-2017 |
| Multiple Sclerosis Therapeutics Market in India: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| Indian Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Therapeutics: 2018 to 2025 |
| Indian Multiple Sclerosis Therapeutics Historic Market Review by Therapeutics in US$ Million: 2009-2017 |
| Multiple Sclerosis Therapeutics Market in India: Percentage Share Breakdown of Sales by Therapeutics for 2009, 2019, and 2025 |
| South Korea |
| Multiple Sclerosis Therapeutics Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025 |
| South Korean Multiple Sclerosis Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017 |
| Multiple Sclerosis Therapeutics Market Share Distribution in South Korea by Drug Class: 2009 VS 2019 VS 2025 |
| Multiple Sclerosis Therapeutics Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Therapeutics for the Period 2018-2025 |
| South Korean Multiple Sclerosis Therapeutics Historic Market Analysis in US$ Million by Therapeutics: 2009-2017 |
| Multiple Sclerosis Therapeutics Market Share Distribution in South Korea by Therapeutics: 2009 VS 2019 VS 2025 |
| Rest of Asia-Pacific |
| Rest of Asia-Pacific Market for Multiple Sclerosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017 |
| Rest of Asia-Pacific Multiple Sclerosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Rest of Asia-Pacific Market for Multiple Sclerosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Therapeutics for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Therapeutics for the Period 2009-2017 |
| Rest of Asia-Pacific Multiple Sclerosis Therapeutics Market Share Analysis by Therapeutics: 2009 VS 2019 VS 2025 |
| Latin America |
| Latin American Multiple Sclerosis Therapeutics Market Trends by Region/Country in US$ Million: 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017 |
| Latin American Multiple Sclerosis Therapeutics Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 |
| Latin American Multiple Sclerosis Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Historic Market Analysis in Latin America in US$ Million by Drug Class: 2009-2017 |
| Latin American Multiple Sclerosis Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Latin American Multiple Sclerosis Therapeutics Market Growth Prospects in US$ Million by Therapeutics for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Historic Market Analysis in Latin America in US$ Million by Therapeutics: 2009-2017 |
| Latin American Multiple Sclerosis Therapeutics Market by Therapeutics: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Argentina |
| Argentinean Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Argentina in US$ Million by Drug Class: A Historic Review for the Period 2009-2017 |
| Argentinean Multiple Sclerosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Argentinean Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Therapeutics: 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Argentina in US$ Million by Therapeutics: A Historic Review for the Period 2009-2017 |
| Argentinean Multiple Sclerosis Therapeutics Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025 |
| Brazil |
| Multiple Sclerosis Therapeutics Market in Brazil by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Brazilian Multiple Sclerosis Therapeutics Historic Market Scenario in US$ Million by Drug Class: 2009-2017 |
| Brazilian Multiple Sclerosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Multiple Sclerosis Therapeutics Market in Brazil by Therapeutics: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Brazilian Multiple Sclerosis Therapeutics Historic Market Scenario in US$ Million by Therapeutics: 2009-2017 |
| Brazilian Multiple Sclerosis Therapeutics Market Share Analysis by Therapeutics: 2009 VS 2019 VS 2025 |
| Mexico |
| Multiple Sclerosis Therapeutics Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025 |
| Mexican Multiple Sclerosis Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017 |
| Mexican Multiple Sclerosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Multiple Sclerosis Therapeutics Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Therapeutics for the Period 2018-2025 |
| Mexican Multiple Sclerosis Therapeutics Historic Market Analysis in US$ Million by Therapeutics: 2009-2017 |
| Mexican Multiple Sclerosis Therapeutics Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025 |
| Rest of Latin America |
| Rest of Latin America Multiple Sclerosis Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025 |
| Multiple Sclerosis Therapeutics Market in Rest of Latin America by Drug Class: A Historic Review in US$ Million for 2009-2017 |
| Rest of Latin America Multiple Sclerosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Rest of Latin America Multiple Sclerosis Therapeutics Market Estimates and Projections in US$ Million by Therapeutics: 2018 to 2025 |
| Multiple Sclerosis Therapeutics Market in Rest of Latin America by Therapeutics: A Historic Review in US$ Million for 2009-2017 |
| Rest of Latin America Multiple Sclerosis Therapeutics Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025 |
| Middle East |
| The Middle East Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 |
| Multiple Sclerosis Therapeutics Market in the Middle East by Region/Country in US$ Million: 2009-2017 |
| The Middle East Multiple Sclerosis Therapeutics Market Share Breakdown by Region/Country: 2009, 2019, and 2025 |
| The Middle East Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025 |
| The Middle East Multiple Sclerosis Therapeutics Historic Market by Drug Class in US$ Million: 2009-2017 |
| Multiple Sclerosis Therapeutics Market in the Middle East: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| The Middle East Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Therapeutics: 2018 to 2025 |
| The Middle East Multiple Sclerosis Therapeutics Historic Market by Therapeutics in US$ Million: 2009-2017 |
| Multiple Sclerosis Therapeutics Market in the Middle East: Percentage Share Breakdown of Sales by Therapeutics for 2009, 2019, and 2025 |
| Iran |
| Iranian Market for Multiple Sclerosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Iran: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017 |
| Iranian Multiple Sclerosis Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Iranian Market for Multiple Sclerosis Therapeutics: Annual Sales Estimates and Projections in US$ Million by Therapeutics for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Iran: Historic Sales Analysis in US$ Million by Therapeutics for the Period 2009-2017 |
| Iranian Multiple Sclerosis Therapeutics Market Share Analysis by Therapeutics: 2009 VS 2019 VS 2025 |
| Israel |
| Israeli Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Israel in US$ Million by Drug Class: A Historic Review for the Period 2009-2017 |
| Israeli Multiple Sclerosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Israeli Multiple Sclerosis Therapeutics Market Estimates and Forecasts in US$ Million by Therapeutics: 2018-2025 |
| Multiple Sclerosis Therapeutics Market in Israel in US$ Million by Therapeutics: A Historic Review for the Period 2009-2017 |
| Israeli Multiple Sclerosis Therapeutics Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025 |
| Saudi Arabia |
| Saudi Arabian Multiple Sclerosis Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Historic Market Analysis in Saudi Arabia in US$ Million by Drug Class: 2009-2017 |
| Saudi Arabian Multiple Sclerosis Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Saudi Arabian Multiple Sclerosis Therapeutics Market Growth Prospects in US$ Million by Therapeutics for the Period 2018-2025 |
| Multiple Sclerosis Therapeutics Historic Market Analysis in Saudi Arabia in US$ Million by Therapeutics: 2009-2017 |
| Saudi Arabian Multiple Sclerosis Therapeutics Market by Therapeutics: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| United Arab Emirates |
| Multiple Sclerosis Therapeutics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025 |
| United Arab Emirates Multiple Sclerosis Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017 |
| Multiple Sclerosis Therapeutics Market Share Distribution in United Arab Emirates by Drug Class: 2009 VS 2019 VS 2025 |
| Multiple Sclerosis Therapeutics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Therapeutics for the Period 2018-2025 |
| United Arab Emirates Multiple Sclerosis Therapeutics Historic Market Analysis in US$ Million by Therapeutics: 2009-2017 |
| Multiple Sclerosis Therapeutics Market Share Distribution in United Arab Emirates by Therapeutics: 2009 VS 2019 VS 2025 |
| Rest of Middle East |
| Multiple Sclerosis Therapeutics Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025 |
| Rest of Middle East Multiple Sclerosis Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017 |
| Rest of Middle East Multiple Sclerosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Multiple Sclerosis Therapeutics Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Therapeutics for the Period 2018-2025 |
| Rest of Middle East Multiple Sclerosis Therapeutics Historic Market Analysis in US$ Million by Therapeutics: 2009-2017 |
| Rest of Middle East Multiple Sclerosis Therapeutics Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025 |
| Africa |
| African Multiple Sclerosis Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025 |
| Multiple Sclerosis Therapeutics Market in Africa by Drug Class: A Historic Review in US$ Million for 2009-2017 |
| African Multiple Sclerosis Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| African Multiple Sclerosis Therapeutics Market Estimates and Projections in US$ Million by Therapeutics: 2018 to 2025 |
| Multiple Sclerosis Therapeutics Market in Africa by Therapeutics: A Historic Review in US$ Million for 2009-2017 |
| African Multiple Sclerosis Therapeutics Market Share Breakdown by Therapeutics: 2009 VS 2019 VS 2025 |
| IV. COMPETITION |
| Total Companies Profiled : 45 Click here to request a full table of contents and more details on this project. |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com